| Total |
| MMR (2 doses or more)d |
86.9 |
88.9 |
89.3 |
89.1 |
90.5 |
— |
— |
87.1 |
87.8 |
87.8 |
— |
— |
89.6 |
89.3 |
91.1 |
| HepB (3 doses or more)e |
81.3 |
87.6 |
87.9 |
89.9 |
91.6 |
— |
— |
86.7 |
88.3 |
89.0 |
— |
— |
88.0 |
90.3 |
92.4 |
| Var (1 dose or more)f |
65.5 |
75.7 |
81.9 |
87.0 |
90.5 |
— |
— |
77.0 |
82.9 |
86.7 |
— |
— |
82.9 |
87.6 |
91.2 |
| Var (2 doses or more)g |
— |
— |
34.1 |
48.6 |
58.1 |
— |
— |
35.8 |
46.2 |
53.8 |
— |
— |
33.9 |
48.7 |
58.9 |
| Td or Tdap (1 dose or more)h |
60.1 |
72.3 |
72.2 |
76.2 |
81.2 |
— |
— |
70.9 |
71.8 |
76.8 |
— |
— |
72.7 |
77.0 |
82.2 |
| Tdap (1 dose or more)i |
10.8 |
30.4 |
40.8 |
55.6 |
68.7 |
— |
— |
38.6 |
52.8 |
64.7 |
— |
— |
41.2 |
56.1 |
69.5 |
| MenACWY (1 dose or more)j |
11.7 |
32.4 |
41.8 |
53.6 |
62.7 |
— |
— |
40.8 |
52.5 |
62.0 |
— |
— |
42.0 |
63.8 |
62.9 |
| HPV (1 dose or more)—females onlyk |
— |
25.1 |
37.2 |
44.3 |
48.7 |
— |
— |
46.4 |
51.9 |
51.8 |
— |
— |
35.8 |
42.5 |
47.7 |
| HPV (3 doses or more)—females onlyl |
— |
— |
17.9 |
26.7 |
32.0 |
— |
— |
14.9 |
25.5 |
28.2 |
— |
— |
18.6 |
26.8 |
32.9 |
| White, non-Hispanic |
| MMR (2 doses or more)d |
— |
— |
89.9 |
90.2 |
91.6 |
— |
— |
89.2 |
86.7 |
90.4 |
— |
— |
89.7 |
90.4 |
91.7 |
| HepB (3 doses or more)e |
— |
— |
88.1 |
90.2 |
92.7 |
— |
— |
88.4 |
87.4 |
90.8 |
— |
— |
87.9 |
90.5 |
92.8 |
| Var (1 dose or more)f |
— |
— |
82.8 |
88.5 |
91.2 |
— |
— |
74.4 |
79.3 |
85.6 |
— |
— |
82.9 |
88.9 |
91.7 |
| Var (2 doses or more)g |
— |
— |
31.6 |
48.8 |
59.2 |
— |
— |
— |
34.2 |
42.9 |
— |
— |
— |
49.1 |
60.4 |
| Td or Tdap (1 dose or more)h |
— |
— |
71.6 |
76.5 |
80.9 |
— |
— |
64.5 |
68.6 |
70.2 |
— |
— |
72.3 |
77.1 |
82.1 |
| Tdap (1 dose or more)i |
— |
— |
41.7 |
55.8 |
68.6 |
— |
— |
32.8 |
49.5 |
57.5 |
— |
— |
42.5 |
56.1 |
69.9 |
| MenACWY (1 dose or more)j |
— |
— |
39.7 |
53.1 |
61.2 |
— |
— |
32.8 |
47.1 |
50.3 |
— |
— |
48.9 |
53.3 |
62.5 |
| HPV (1 dose or more)—females onlyk |
— |
— |
35.0 |
43.9 |
45.8 |
— |
— |
37.3 |
52.5 |
39.4 |
— |
— |
35.7 |
43.0 |
46.6 |
| HPV (3 doses or more)—females onlyl |
— |
— |
19.5 |
29.1 |
32.4 |
— |
— |
— |
— |
25.7 |
— |
— |
— |
— |
32.8 |
| Black, non-Hispanic |
| MMR (2 doses or more)d |
— |
— |
89.1 |
86.3 |
90.8 |
— |
— |
89.1 |
84.4 |
92.1 |
— |
— |
88.6 |
86.9 |
90.2 |
| HepB (3 doses or more)e |
— |
— |
86.0 |
88.9 |
90.9 |
— |
— |
86.9 |
86.6 |
90.0 |
— |
— |
85.8 |
89.8 |
91.3 |
| Var (1 dose or more)f |
— |
— |
74.0 |
82.4 |
89.2 |
— |
— |
72.7 |
79.8 |
87.0 |
— |
— |
74.8 |
82.8 |
89.5 |
| Var (2 doses or more)g |
— |
— |
35.0 |
43.9 |
55.3 |
— |
— |
— |
44.4 |
60.3 |
— |
— |
— |
44.2 |
51.8 |
| Td or Tdap (1 dose or more)h |
— |
— |
71.4 |
72.5 |
80.5 |
— |
— |
68.9 |
69.5 |
80.1 |
— |
— |
71.9 |
74.8 |
80.1 |
| Tdap (1 dose or more)i |
— |
— |
36.0 |
52.7 |
66.9 |
— |
— |
39.0 |
47.7 |
68.1 |
— |
— |
33.4 |
55.6 |
66.0 |
| MenACWY (1 dose or more)j |
— |
— |
43.1 |
53.0 |
63.4 |
— |
— |
38.8 |
52.0 |
66.5 |
— |
— |
40.3 |
53.8 |
61.4 |
| HPV (1 dose or more)—females onlyk |
— |
— |
35.7 |
44.6 |
48.9 |
— |
— |
53.0 |
51.6 |
55.7 |
— |
— |
31.2 |
40.7 |
44.5 |
| HPV (3 doses or more)—females onlyl |
— |
— |
14.9 |
23.1 |
30.2 |
— |
— |
— |
— |
31.6 |
— |
— |
— |
— |
28.6 |
| Hispanic |
| MMR (2 doses or more)d |
— |
— |
87.5 |
87.6 |
86.2 |
— |
— |
83.9 |
90.6 |
83.5 |
— |
— |
90.4 |
85.4 |
88.1 |
| HepB (3 doses or more)e |
— |
— |
89.8 |
90.0 |
88.9 |
— |
— |
86.2 |
90.3 |
87.8 |
— |
— |
92.1 |
89.8 |
91.0 |
| Var (1 dose or more)f |
— |
— |
84.5 |
85.5 |
90.6 |
— |
— |
80.0 |
84.6 |
88.1 |
— |
— |
88.9 |
85.6 |
92.1 |
| Var (2 doses or more)g |
— |
— |
38.5 |
49.7 |
56.2 |
— |
— |
— |
49.7 |
55.8 |
— |
— |
— |
49.4 |
56.7 |
| Td or Tdap (1 dose or more)h |
— |
— |
74.1 |
76.7 |
82.4 |
— |
— |
74.8 |
74.2 |
78.9 |
— |
— |
75.7 |
77.4 |
85.0 |
| Tdap (1 dose or more)i |
— |
— |
41.9 |
55.6 |
69.6 |
— |
— |
40.4 |
55.8 |
67.4 |
— |
— |
44.0 |
54.8 |
70.6 |
| MenACWY (1 dose or more)j |
— |
— |
46.8 |
55.9 |
66.1 |
— |
— |
45.0 |
56.2 |
67.4 |
— |
— |
44.7 |
55.9 |
64.4 |
| HPV (1 dose or more)—females onlyk |
— |
— |
44.4 |
45.5 |
56.2 |
— |
— |
45.9 |
52.2 |
57.9 |
— |
— |
39.3 |
42.0 |
53.5 |
| HPV (3 doses or more)—females onlyl |
— |
— |
14.7 |
23.4 |
29.5 |
— |
— |
— |
— |
27.1 |
— |
— |
— |
— |
32.9 |
| — Not available. |
| a Based on family income and household size using Census Bureau poverty thresholds for the year of data collection. |
| b The revised 1997 Office of Management and Budget (OMB) Standards for Data on Race and Ethnicity were used. Persons could select one or more from the following racial groups: White, Black or African American, American Indian or Alaska Native, Asian, or Native Hawaiian or Other Pacific Islander. Persons of Hispanic origin may be of any race. Included in the total but not shown separately are American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander and "Two or more races" due to the small sample size. Data on race and Hispanic origin are collected separately but combined for reporting. |
| c Data collection for 2006 and 2007 only included the fourth quarter of each year. |
| d Includes 2 doses (or more) of measles-mumps-rubella vaccine received at any age. |
| e Includes 3 doses (or more) of hepatitis B vaccine received at any age. |
| f Includes 1 dose (or more) of varicella vaccine received at any age and without a history of varicella disease. |
| g Includes 2 doses (or more) of varicella vaccine received at any age and without a history of varicella disease. |
| h Includes 1 dose (or more) of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since age 10. |
| i Includes 1 dose (or more) of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since age 10. |
| j Includes 1 dose (or more) of meningococcal conjugate vaccine (MenACWY) and meningococcal-unknown type vaccine. |
| k Includes 1 dose (or more) quadrivalent or bivalent human papillomavirus vaccine (HPV). Percentages reported among females only that initiated the 3-dose series. |
| l Includes 3 doses (or more) quadrivalent or bivalent human papillomavirus vaccine (HPV). Percentages reported among females only that completed 3-dose series. |
| NOTE: Data includes routinely recommended vaccines (Tdap, MenACWY, HPV—females only) and early childhood vaccines (MMR, HepB, Var) for catch-up coverage estimates. |
| SOURCE: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases and National Center for Health Statistics, National Immunization Survey—Teen. |